Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential

Ostaijen-ten Dam, M.M. van; Prins, H.J.; Boerman, G.H.; Vervat, C.; Pende, D.; Putter, H.; ... ; Schilham, M.W. (2016)

Article / Letter to editor

• interleukin-2
• interleukin-15
• natural killer cells
• CliniMACS
• acute leukemia
• clinical protocol
• good manufacturing practice

• All authors: Ostaijen-ten Dam, M.M. van; Prins, H.J.; Boerman, G.H.; Vervat, C.; Pende, D.; Putter, H.; Lankester, A.; Tol, M.J.D. van; Zwaginga, J.J.; Schilham, M.W.
• Date: 2016-03-31
• Journal: Journal of Immunotherapy
• Volume: 39
• Issue: 2
• Pages: 90 - 100
• DOI: doi:10.1097/CJI.0000000000000110